CD20 is expressed on both anti-tumor B cells and tBregs, and targeting CD20 B cells with CXCL13-coupled CpG-ODN can enrich and inactivate tBregs, thereby controlling tumor immune escape (41). This evidence concerns the gene CXCL13 and neoplasm.